Hemab Therapeutics is developing therapeutics for patients with rare bleeding and thrombotic disorders. The body’s bleeding and thrombosis pathway is fine-tuned with numerous points within that can fail and cause disease. Hemab is using technological advancements to provide prophylactic treatments and functional cures for the full spectrum of genetically driven bleeding and thrombotic disorders. The therapeutic candidates bind the body’s native clotting factors with high specificity and affinity to balance endogenous clotting factors to the point of injury. Hemab is working to develop five clinical assets by 2025.

Hemab Therapeutics

As 2024 comes to a close, we reflect on a year of steady progress toward improving the lives of those living with rare bleeding disorders. This year has been about building stronger connections, deepening our understanding of the community’s needs, and advancing the research that will shape the future of care. We’ve been urgently working because there is not a minute to lose.
 
At Hemab, we are grateful for the patients, families, and healthcare professionals who are making our work possible. We are driven by the unwavering commitment shown by our collaborators and trial participants, who are making the development of HMB-001 and HMB-002 a reality.

Looking ahead to 2025, we are driving forward with a clear purpose: advancing HMB-001 and HMB-002 in the clinic, evaluating their potential to make a meaningful difference for those living with rare bleeding disorders. As we explore new possibilities within our pipeline, our focus stays centered on advancing innovative solutions that meet critical unmet patient needs and drive transformative progress in care. Learn more at https://hemab.com/  

Imagine facing unexplained bruises that linger, bleeding that doesn’t stop after a minor cut, or periods so heavy they can end in the hospital. This is the reality of Von Willebrand Disease (VWD), a bleeding disorder that often hides in plain sight, leaving many undiagnosed for years. The journey to answers can feel like a maze, with confusing symptoms and missed diagnoses creating frustration and uncertainty. Even after diagnosis, the path forward isn’t always clear—gaps in care and awareness leave patients and families searching for guidance. Managing VWD means navigating these challenges with vigilance, education, and the support needed to reclaim a sense of control.

At Hemab, we’re committed to helping those impacted by VWD regain control through our work on HMB-002, an investigational therapy designed to elevate endogenous von Willebrand factor levels. Our team is dedicated to advancing this research with our clinical trial VELORA-Discover, an observational study in individuals with Type 1 VWD. To learn more or enroll, contact clinicaltrials@hemab.com or visit https://lnkd.in/eN6tuMqp

Hemab Therapeutics Announces First Drug Candidate: HMB-001, a Novel Bispecific Antibody with Potential for Treatment of Rare Bleeding Disorders - PR Newswire

John Maraganore is Embracing the Role of Biotech’s Newest Grandfather - BioSpace

Hemab Therapeutics - The Pharma Letter

Danish deep tech startup nabs $135M in Series B to advance first prophylactic treatments for underserved - ArcticStartup

Hemab Therapeutics Announces $135M Series B Financing to Advance First Prophylactic Treatments for Underserved Bleeding and Thrombotic Disorders - PR Newswire

Hemab Therapeutics Announces First Patient Dosed in Phase 2 Clinical Study Investigating HMB-001 for the Treatment of Glanzmann Thrombasthenia - PR Newswire

Careers

Hemab Therapeutics raises $135 million in Series B financing - The Pharma Letter

There is not a moment to waste and our commitment to advancing care for rare bleeding disorders has never been stronger. With limited options available for those living with Glanzmann thrombasthenia, von Willebrand disease, and others, we’re here to close that gap and leapfrog treatment into the 21st century. Follow along with Hemab and our CEO Benny Sorensen as we work to deliver the innovation patients deserve.

Hemab reports positive Phase I Glanzmann thrombasthenia therapy data - Clinical Trials Arena

As we imagine what the world might look like in 2118, we can’t help but dream about flying cars and advanced technologies.

However, if we look back to 1918 when Eduard Glanzmann first identified Glanzmann Thrombasthenia (GT), we find that a century later patients are still waiting for accessible prophylactic treatments.

At Hemab, we are dedicated to changing the narrative. As CEO Benny Sorensen said, in our five years of operation, we've undertaken numerous natural history studies, amplifying the voices of individuals living with GT. 

Our mission doesn’t stop here; we’re actively working to advance therapeutics into the 21st century. Currently we are focused on enrolling participants for our Phase 2 study of HMB-001, moving closer to innovative solutions for those affected by this condition.

To enroll or learn more, reach out to clinicaltrials@hemab.com or visit https://lnkd.in/ep3zSGdP

Hemab vibes? We are drug hunters who are setting the standard in preventative treatments for bleeding disorders. Passionate, visionary, experienced and curious, at Hemab our talent has contributed to 60% of approved drugs in this space—driven by a relentless commitment to science, innovation, and patients. Join us in creating breakthroughs that matter. Learn more at https://lnkd.in/e7ynhmFS

Hemab Therapeutics Presents New Preclinical Research Demonstrating Effects of Its Bispecific Antibody HMB-001 in Factor VII Deficiency - PR Newswire

Hemab Therapeutics to Present New Preclinical Data on HMB-001 in Factor VII Deficiency and Initial Findings from Glanzmann Thrombasthenia Natural History Study at the International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress - PR Newswire

Hemab is back in San Diego at the 66th American Society of Hematology Annual Meeting and Exposition–the world's largest gathering of hematologist experts! 

On December 9 at 6pm, we will present a poster (Abstract #3953.1) on the Phase 2 study of HMB-001 in participants with Glanzmann Thrombasthenia– an important step towards our mission to deliver preventative treatments to patients with rare bleeding disorders. 

#ASH24 provides a global platform to share our latest research on HMB-001, connect with industry leaders, and explore new possibilities for the future of blood disorder treatments. You can learn more about our vision for this future at https://hemab.com/.

Be sure to stop by and say hello, we look forward to seeing you!

With $135M in fresh funds, Hemab aims to leapfrog drug development for neglected blood disorders - Fierce Biotech

Living with Glanzmann Thrombasthenia (GT), a rare, inherited bleeding disorder, can be isolating. Help make voices in the community better understood. Gaining insight into the patient perspective will help advance research for this and the next generation of GT patients.

Please take a few minutes to complete the Voices of GT Survey and contribute to research that aims to better understand life with GT and develop treatments that truly meet patient needs. Start the survey here: https://lnkd.in/eQ54tTVZ

Your voice can make a difference.

Hemab Secures $135M for Neglected Bleeding Disorders - BioSpace

Debilitating fatigue that keeps patients bedridden, the emotional burden of bruising that draws unwanted attention. These are some of the daily challenges shared by those living with Glanzmann’s thrombasthenia (GT). In a recent Haemnet GT 360 study paper, we learned about these personal accounts which underscore the significant unmet need in GT.

Thank you Haemnet for conducting this important study, and to the patients who shared their lived experiences to help raise awareness and drive change.

Read more qualitative results from the GT 360 study here https://lnkd.in/eQhTBJAn and learn about our pipeline at https://hemab.com/ 

Log in

Bleeding events don’t pause during holidays—sometimes, they steal them entirely.

People living with Glanzmann thrombasthenia (GT) hide extraordinary burdens – quietly adapting, canceling trips, and enduring hospital stays.

For many years, this went unrecognized until now. 

Thanks to the recent partnership with the Glanzmann's Research Foundation, Inc. and the CHES Foundation, Inc., we are able to have open dialogue about GT. Here are a few real-life examples we captured thanks to Sano Genetics:

• A GI bleed turned a holiday trip into a week-long hospital stay
• A sudden bleed in both ears while flying
• Anemia canceled a long-awaited family vacation
• A family unwrapped presents at the hospital 

If you’re living with GT, share your story to help create a future without these limitations: https://lnkd.in/eQ54tTVZ

Hemab Therapeutics Appoints Dr. Akshay Vaishnaw to Board of Directors and Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference - PR Newswire

Hemab Therapeutics Presents Positive Phase 1 Results for HMB-001 in Glanzmann Thrombasthenia at 2024 EAHAD Annual Congress - PR Newswire

Hemab Therapeutics Announces First Patient Dosed in Phase 1/2 Study of HMB-001 to Treat Bleeding Disorder Glanzmann Thrombasthenia - PR Newswire

here

Hemab Therapeutics

Business:

Drug notes:

About: